Estrella Immunopharma (Estrella Immunopharma) EV-to-EBIT : -6.12 (As of May. 08, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Estrella Immunopharma's Enterprise Value is $17.70 Mil. Estrella Immunopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.89 Mil. Therefore, Estrella Immunopharma's EV-to-EBIT for today is -6.12.

The historical rank and industry rank for Estrella Immunopharma's EV-to-EBIT or its related term are showing as below:

ESLA' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.95 Med: 0 Max: 0
Current: -6.12

ESLA's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.54 vs ESLA: -6.12

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Estrella Immunopharma's Enterprise Value for the quarter that ended in Dec. 2023 was $30.03 Mil. Estrella Immunopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.89 Mil. Estrella Immunopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.63%.

Estrella Immunopharma EV-to-EBIT Historical Data

The historical data trend for Estrella Immunopharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma EV-to-EBIT Chart

Estrella Immunopharma Annual Data

Trend

Jun21

EV-to-EBIT

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-10.39

Competitive Comparison of Estrella Immunopharma's EV-to-EBIT

For the Biotechnology subindustry, Estrella Immunopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Estrella Immunopharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's EV-to-EBIT falls into.

Estrella Immunopharma EV-to-EBIT Calculation

Estrella Immunopharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	17.702	/	-2.891
	=	-6.12

Estrella Immunopharma's current Enterprise Value is $17.70 Mil.
Estrella Immunopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.

Estrella Immunopharma (NAS:ESLA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Estrella Immunopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-2.891	/	30.027332
	=	-9.63 %

Estrella Immunopharma's Enterprise Value for the quarter that ended in Dec. 2023 was $30.03 Mil.
Estrella Immunopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.

Estrella Immunopharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines